Replies to post #57924 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Good post! I concur. To further add... there will likely be differing dosage requirements of both 2-73 and donepezil (if prescribed), depending upon the patient, which would suggest they be prescribed separately.

[WolfWayne]

Regarding royalties otherwise owed to Dr. Vamvakides, the non-patentability of the combination drug may turn out to benefit Anavex and her shareholders. Anavex was clearly assigned rights to 2-73; however it seems Dr. Vamvakides compensation for the 2-73 plus anything left some wiggle room for Anavex to renegotiate pre-existing agreements with Dr. Vamvakides. If I remember correctly, Dr. Vamvakides filed a patent similar to the 2-73 Plus patent probably to ensure Anavex didn't exclude Dr. Vamvakides from losing influence and royalty rights. Now that the 2-73 plus patent has received a "final" rejection the 2-73 standalone rebuttal should acquiesce the concerns of the USPTO and put a rest to Dr. Vamvakides worries, if indeed he still had any. Remember, 2-73 was in many ways the life work of Dr. Vamvakides. His legacy is likely more important than cash.

In short, it seems Dr. Missling has been right all along - "there is no patent issue".